--- a
+++ b/clusters/9knumclustersv2/clust_1571.txt
@@ -0,0 +1,50 @@
+Gene therapy using an integrating vector Allogeneic hematopoietic stem cell transplant at any time not permitted
+Prior allogeneic hematopoietic cell transplant
+Prior allogeneic hematopoietic cell transplant
+Previous allogeneic hematopoietic stem cell transplant
+Prior allogeneic hematopoietic stem cell transplants
+Allogeneic hematopoietic stem cell transplant
+Prior allogeneic transplant for any hematopoietic disorder
+Patients who have undergone a prior allogeneic hematopoietic or (other organ) transplant
+Previous allogeneic hematopoietic cell transplant (HCT)
+Has previously received an allogeneic hematopoietic cell transplant or chimeric antigen receptor-modified (CAR)-T cells
+Prior allogeneic hematopoietic cell transplant.
+Patients who have received a prior allogeneic hematopoietic stem cell transplant (HSCT) and who have either rejected their grafts or who have become tolerant of their grafts with no active GVHD requiring immunosuppressive therapy
+Preceding allogeneic hematopoietic stem cell transplant (HSCT)
+No subjects who have received an allogeneic hematopoietic stem cell transplant are eligible
+Received an allogeneic hematopoietic transplant within  months of screening
+Patients undergoing haploidentical allogeneic hematopoietic stem cell transplants are not eligible; patients undergoing < / HLA allele matched allogeneic transplant are not eligible
+Prior allogeneic transplant for any hematopoietic disorder
+Prior allogeneic hematopoietic stem cell transplant.
+Subject who has history of organ transplant or allogeneic hematopoietic stem cell transplantation.
+Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ?  months.
+Patients who have previously undergone allogeneic hematopoietic stem cell transplant will be excluded from this study
+Allogeneic hematopoietic stem cell transplant within  days prior to leukapheresis
+Prior history of allogeneic hematopoietic stem cell transplant (HSCT).
+Recipients of prior allogeneic hematopoietic stem cell transplant (HSCT) with active acute or chronic GVHD
+Prior allogeneic hematopoietic stem cell transplant
+Prior allogeneic hematopoietic stem cell transplant
+Prior allogeneic hematopoietic stem cell transplant.
+Prior allogeneic hematopoietic stem cell transplant (HSCT)
+Prior allogeneic hematopoietic stem cell transplantation (allogeneic stem cell transplant)
+Prior allogeneic hematopoietic stem cell transplant
+At least  days after receiving any allogeneic hematopoietic stem cell transplant AND
+Previous allogeneic hematopoietic stem cell transplant (HSCT transplant).
+Allogeneic hematopoietic stem cell transplant or Donor Lymphocyte Infusion within  days prior to to the first dose of study drug
+Prior allogeneic hematopoietic stem cell transplant
+Prior allogeneic hematopoietic stem cell transplant within </= months before first dose of study drug (Subjects must have completed immunosuppressive therapy before enrollment.
+Prior allogeneic hematopoietic cell transplant
+Not currently a candidate for allogeneic hematopoietic stem cell transplant (HSCT).
+Previous allogeneic hematopoietic transplant within  days of study enrollment, Active GVHD requiring treatment.
+Previous allogeneic hematopoietic transplant within  days. Active GVHD requiring treatment
+Any previous allogeneic hematopoietic stem cell transplant.
+Patients must have received allogeneic hematopoietic stem cell transplant and be greater than  days post-transplant at the time of registration
+Scheduled to undergo an allogeneic hematopoietic stem cell transplant for any cancer or non-cancer illness
+Prior allogeneic hematopoietic stem cell transplant (HSCT)
+Allogeneic hematopoietic cell transplant recipient
+Prior allogeneic hematopoietic cell transplant
+Prior allotransplant, including allogeneic hematopoietic cell transplant or solid organ allogeneic transplant
+Diagnosis of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for whom an allogeneic hematopoietic stem cell transplant using a reduced intensity conditioning is planned or has been performed and patient is prior to day  post-transplant
+Patient must have a diagnosis that is managed with an alternative donor allogeneic hematopoietic cell transplant
+Prior allogeneic hematopoietic stem cell transplant.
+Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ?  months prior to starting CC-.